Thursday, May 27, 2021
Cocrystal Pharma Inc. (COCP)
Transferring Coverage and Reiterating Rating
Cocrystal Pharma Inc is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks.
Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
A portfolio of anti-viral products with novel mechanisms of action. The company has six antiviral products in development for Hepatitis C, Influenza, COVID-19, and Norovirus that are in development both as cocktails or monotherapies. We are transferring coverage and reiterating our rating on Cocrystal Pharmaceuticals. Our price target remains.
Proprietary technology. Its technology is based on Noble-prize-winning discoveries by Dr. Roger Kornberg, Chief Scientist and Chairman of its Scientific Advisory Board. It product pipeline has been developed using its proprietary structure-based design, based on X-ray crystallogrpahy and protein engineering …
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
